ECSS
PTCT icon

Eurizon Capital SGR SpA’s PTC Therapeutics PTCT Stock Holding History

Eurizon Capital SGR SpA’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$129K Hold
1,580
– – ﹤0.01% 847
2026
Q1 		$104K Hold
1,580
– – ﹤0.01% 886
2025
Q4 		$120K Buy
+1,580
New +$115K ﹤0.01% 749

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Eurizon Capital SGR SpA's PTCT Position: Q2 2026 in Review

Eurizon Capital SGR SpA held its PTC Therapeutics (PTCT) position steady in Q2 2026 at 1,580 shares worth $129K. The position accounts for ﹤0.01% of the portfolio, ranked #847.

Eurizon Capital SGR SpA first reported a position in PTCT in Q4 2025 and has held it in 3 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Eurizon Capital SGR SpA held 1,580 shares of PTC Therapeutics worth $129K as of Q2 2026.
  • Eurizon Capital SGR SpA left its PTC Therapeutics share count unchanged in Q2 2026.
  • PTC Therapeutics made up ﹤0.01% of Eurizon Capital SGR SpA's portfolio in Q2 2026, its #847 holding.
  • Eurizon Capital SGR SpA first reported a position in PTC Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Eurizon Capital SGR SpA's 13F filing for Q2 2026, filed 29 Jul 2026.